While sales force optimization is a challenge that has been faced by all sectors to which sales networks are critical, for the pharmaceutical industry, this challenge has become a vital necessity.
The laboratories face growing pressures that intensify the struggle to be competitive in the sector. First of al, the regulatory environment of medical visits is becoming increasingly strict. Also, control of sanitary costs that Public Administrations have made their goal has translated into an increase in fiscal pressure on the pharmaceutical industry and, similarly, into a clear support for the commercialization of generic medications.
To this increasingly strict environment is added the extremely complex process of research, launching, and commercialization of the product. The R&D activities developed by the laboratories, starting with the first research work on a molecule, until the medication finally sees the light of day, usually last an average of about 10 years. Given that the maximum time allowed by law to exploit a medication with a registered brand name is 20 years, the pharmaceutical industry has only an average of 10 years to get the most out of a medication, before it irrevocably becomes a generic specialty.
Public Administration’s support of generics –because of the savings they entail- together with the “sales war” these medications have unleashed –any laboratory, regardless of its size or know-how, can “copy” a generic medication-, has doubled the pressures on the sector: in Spain, the growth of generic medications is exponential.
In this context, the laboratories are finding few channels in order to maintain a sustained growth rate… After investment in R&D, the sales force almost always constitutes its largest budget item, which is why every laboratory is focusing its attention on it, as a means to optimize costs.
Faced with radical decisions such as the staff re-structuring, Customer Intelligence actions are increasingly becoming the alternative the majority of laboratories are adopting. The decision of the big pharmaceutical companies to optimize their sales networks not only follows criteria related to mere economic efficiency, but it also directly affects the well-being of the patient, who is able to access better service and attention.
Customer Intelligence actions act fundamentally in two fields:
Daemon Quest has ascertained that Customer Intelligence techniques in the pharmaceutical sector are increasingly common; in fact, six of the laboratories that are applying Sales Force Effectiveness programs were ranked among the top positions in terms of sales growth last year, according to data recently disclosed by IMSvii.